Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CARANASDAQ:CRONTSE:TEVNASDAQ:TLRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARACara Therapeutics$15.19$8.13▼$19.08$24.33M0.4123,063 shs237,144 shsCRONCronos Group$1.90-0.5%$1.94$1.60▼$2.54$732.80M1.041.34 million shs885,477 shsTEVTervitaC$0.00C$1.69▼C$6.46C$672.00MN/A79,738 shs15,893 shsTLRYTilray Brands$0.40-2.8%$0.43$0.35▼$2.15$403.30M1.8329.72 million shs12.80 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARACara Therapeutics0.00%0.00%0.00%+3.30%+52.87%CRONCronos Group0.00%+2.15%-7.32%+6.15%-18.10%TEVTervita0.00%0.00%0.00%0.00%0.00%TLRYTilray Brands0.00%+11.31%-13.75%-39.54%-76.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCARACara Therapeutics0.305 of 5 stars0.00.00.04.20.60.80.0CRONCronos Group2.4601 of 5 stars0.05.00.00.02.60.02.5TEVTervitaN/AN/AN/AN/AN/AN/AN/AN/ATLRYTilray Brands1.8411 of 5 stars3.11.00.00.03.00.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCARACara Therapeutics 0.00N/AN/AN/ACRONCronos Group 0.00N/AN/AN/ATEVTervita 0.00N/AN/AN/ATLRYTilray Brands 2.25Hold$1.92378.33% UpsideCurrent Analyst Ratings BreakdownLatest TLRY, CARA, TEV, and CRON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/14/2025TLRYTilray BrandsRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral4/9/2025TLRYTilray BrandsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$2.00 ➝ $1.00(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCARACara Therapeutics$7.14M0.00N/AN/A$12.58 per share0.00CRONCronos Group$117.61M6.23N/AN/A$2.90 per share0.66TEVTervitaC$1.36B0.00N/A29.62C$1.58 per share0.00TLRYTilray Brands$788.94M0.51N/AN/A$4.14 per share0.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCARACara Therapeutics-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/ACRONCronos Group$41.08M$0.1314.6263.3332.3139.69%-0.07%-0.07%8/6/2025 (Estimated)TEVTervitaN/A-C$0.01N/AN/AN/AN/AN/AN/AN/ATLRYTilray Brands-$244.98M-$1.05N/AN/AN/A-113.85%-7.40%-6.02%8/4/2025 (Estimated)Latest TLRY, CARA, TEV, and CRON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CRONCronos Group$0.01$0.02+$0.01$0.02$45.44 million$33.62 million4/8/2025Q3 2025TLRYTilray Brands-$0.04-$0.10-$0.06-$0.87$213.38 million$185.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCARACara TherapeuticsN/AN/AN/AN/AN/ACRONCronos GroupN/AN/AN/AN/AN/ATEVTervitaN/AN/AN/AN/AN/ATLRYTilray BrandsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCARACara TherapeuticsN/A4.774.71CRONCronos GroupN/A27.8026.75TEVTervita440.441.000.86TLRYTilray Brands0.122.621.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCARACara Therapeutics44.66%CRONCronos Group8.71%TEVTervitaN/ATLRYTilray Brands9.35%Insider OwnershipCompanyInsider OwnershipCARACara Therapeutics3.10%CRONCronos Group6.90%TEVTervitaN/ATLRYTilray Brands0.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCARACara Therapeutics804.57 million4.43 millionOptionableCRONCronos Group450385.68 million359.07 millionOptionableTEVTervita36,800115.66 millionN/ANot OptionableTLRYTilray Brands2,6501.01 billion1.00 billionOptionableTLRY, CARA, TEV, and CRON HeadlinesRecent News About These CompaniesTLRY - Tilray Brands Inc News - MorningstarJune 28 at 8:14 AM | morningstar.comMTilray Brands, Inc. (TLRY) Stock Declines While Market Improves: Some Information for InvestorsJune 27 at 7:00 PM | zacks.comTilray Brands (NASDAQ:TLRY) Shares Up 3.9% - Should You Buy?June 26 at 3:06 PM | marketbeat.comTilray Brands (NasdaqGS:TLRY) Advances Medical Cannabis Research With New Bioavailability StudyJune 26 at 2:52 PM | finance.yahoo.comTilray Medical Publishes Pioneering Research on the Pharmacokinetics of THC and CBD FormulationsJune 26 at 9:52 AM | finance.yahoo.comMontauk Brewing Celebrates 13 Years of Brewing with Faherty Collaboration and Beach Clean Up with the Surfrider FoundationJune 26 at 8:00 AM | globenewswire.comTLRY Stock - Tilray Brands Inc Stock Price Quote - XTSE - MorningstarJune 26 at 4:51 AM | morningstar.comMHere Is A List Of 3 Canadian Marijuana Stocks To Watch 2025June 25, 2025 | marijuanastocks.comMTilray Medical Launches “Good Supply” Cannabis Brand in GermanyJune 25, 2025 | insidermonkey.comTilray Medical Receives Italy’s First Authorization from the Ministry of Health to Distribute Medical Cannabis Flower for Therapeutic UseJune 24, 2025 | finance.yahoo.comTilray sets medical cannabis milestone in ItalyJune 24, 2025 | msn.comTilray Brands Stock Price, Quotes and Forecasts | NASDAQ:TLRY - BenzingaJune 24, 2025 | benzinga.comTilray Brands (NASDAQ:TLRY) Trading 4% Higher - Should You Buy?June 24, 2025 | marketbeat.comTilray Medical Receives Italy's First Authorization from the Ministry of Health to Distribute Medical Cannabis Flower for Therapeutic UseJune 24, 2025 | globenewswire.comTilray Brands, Inc. Unveils Exciting 2025 Summer Cannabis Collection Featuring Innovative Formats and FlavorsJune 23, 2025 | quiverquant.comQElevate Your Summer with Canada’s Leading Cannabis Brands and Products by Tilray BrandsJune 23, 2025 | financialpost.comFElevate Your Summer with Canada's Leading Cannabis Brands and Products by Tilray BrandsJune 23, 2025 | globenewswire.comTilray Brands (NASDAQ:TLRY) Shares Down 3.2% - Should You Sell?June 20, 2025 | marketbeat.comWhy Tilray Brands, Inc. (TLRY) Dipped More Than Broader Market TodayJune 17, 2025 | zacks.comTensions in Middle East Weigh on TSXJune 17, 2025 | theglobeandmail.comTilray (NASDAQ:TLRY) Shares Down 5.8% - What's Next?June 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTLRY, CARA, TEV, and CRON Company DescriptionsCara Therapeutics NASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Cronos Group NASDAQ:CRON$1.90 -0.01 (-0.52%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$1.90 0.00 (-0.26%) As of 06/27/2025 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Tervita TSE:TEVTervita Corporation operates as an environmentally focused waste service provider in Canada and the United States. It operates through two segments, Energy Services and Industrial Services. The Energy Services segment treats, recovers, and disposes fluids; provides oil terminalling and energy marketing services; processes and disposes solid materials; disposes oilfield-generated waste; offers onsite services using centrifugation or other processes for heavy oil producers involved in mining and in situ production; and purchases and sells oil volumes with treatment, recovery, terminalling, and disposal services. The Industrial Services segment provides site remediation, facility decommissioning, water treatment, sludge and slurry management, bio-remediation and technologies, technical, environmental liability management, emergency response, and rail services, as well as hazardous and non-hazardous waste management, and disposal services. This segment also offers recycling services that include purchase and processing of ferrous and non-ferrous metals recovered from demolition sites and other locations. As of December 31, 2020, the company operated 103 active waste processing, disposal, and industrial facilities, including 44 treatment, recovery, and disposal facilities; eight stand-alone disposal wells; three cavern disposal facilities; eight onsite facilities; 22 engineered landfills; three transfer stations; one naturally occurring radioactive material facility; nine bioremediation facilities; and five metals recycling facilities. It serves oil and gas industry, and industrial and natural resource sectors. The company was formerly known as CCS Corporation and changed its name to Tervita Corporation in March 2012. Tervita Corporation was founded in 1979 and is headquartered in Calgary, Canada.Tilray Brands NASDAQ:TLRY$0.40 -0.01 (-2.84%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$0.40 +0.00 (+0.32%) As of 06/27/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
